HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Lowers Price Target to $5

Benzinga · 10/14 17:22
HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and lowers the price target from $15 to $5.